Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to the Therapeutic Goods Administration, as it weighs a third patent infringement lawsuit to protect its multiple sclerosis drug against generic reproductions.
IVF company Virtus Health has withdrawn its offer to acquire rival Adora Fertility from Healius, citing the competition regulator’s opposition to the takeover.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
Group members in a class action over Bayer’s Essure contraceptives had āa ticking time bombā in their bodies after being implanted with the devices, and all were at risk of developing injuries, a court has heard.
A judge was “mistaken” to find that AFT Pharmaceuticals’ ads for its painkiller Maxigesic were misleading, with the Full Federal Court ruling there was an adequate scientific foundation for the ads’ claims that the drug provided faster, better pain relief than paracetamol and ibuprofen alone.
An alternative therapies clinic in Victoria has been hit with $3 million in penalties for allegedly promoting āpseudo-scientificā treatments to vulnerable people with chronic illnesses in posts on social media and its website.
Victoria’s Alfred and St Vincent’s hospitals are the targets of a new class action filed on behalf of junior doctors alleging they were not paid for unrostered work that included admitting patients and attending to medical emergencies.
Generic drug maker Sandoz AG has filed proceedings seeking the revocation of two patents registered in Australia by German pharmaceutical giant Bayer covering its top-selling blood clot drug Xarelto.
Bristol-Myers Squib unit Celgene Corporation has sued Indian generics giant Dr Reddyās Laboratories for allegedly threatening to infringe eight patents for its blockbuster cancer drug Revlimid, which raked in US$12 billion for the US-based company in revenue last year.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.